Effect of forced titration of nebivolol on response rate in obese hypertensive patients [4]

American Journal of Hypertension

Volumn 16, Issue 1, 2003, Pages 98-100

  Pischon, Tobias ^a   Sharma, Arya M ^a,d   Mansmann, Ulrich ^b   Agrawal, Rahul ^c  

^a HUMBOLDT UNIVERSITY   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c Berlin Chemie AG   (Germany)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; NEBIVOLOL;

ADULT; AIRWAY OBSTRUCTION; BLOOD PRESSURE REGULATION; BODY MASS; BODY WEIGHT; BRADYCARDIA; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; ESSENTIAL HYPERTENSION; FEMALE; HUMAN; HYPERTENSION; LETTER; LIPOPHILICITY; MALE; OBESITY; PHARMACODYNAMICS; PRACTICE GUIDELINE; PRIORITY JOURNAL;

ANTIHYPERTENSIVE AGENTS; BENZOPYRANS; ETHANOLAMINES; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; OBESITY; TITRIMETRY; TREATMENT OUTCOME;

EID: 0037230601     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0895-7061(02)03088-1     Document Type: Letter

References (9)

1. Sharma AM, Pischon T, Engeli S, Scholze J: Choice of drug treatment for obesity-related hypertension: where is the evidence? J Hypertens 2001;19:667-674.
2. Lloyd-Jones DM, Evans JC, Larson MG, O'Donnell CJ, Roccella EJ, Levy D: Differential control of systolic and diastolic blood pressure: factors associated with lack of blood pressure control in the community. Hypertension 2000;36:594-599.
3. Bowman AJ, Chen CP, Ford GA: Nitric oxide mediated venodilator effects of nebivolol. Br J Clin Pharmacol 1994;38:199-204.
4. Mangrella M, Rossi F, Fici F: Pharmacology of nebivolol. Pharmacol Res 1998;38:419-431.
5. Ware JE Jr, Sherbourne CD: The MOS 36-item Short-Form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992;30:473-483.
6. Van Nueten L, Dupont AG, Vertommen C, Goyvaerts H, Robertson JI: A dose-response trial of nebivolol in essential hypertension. J Hum Hypertens 1997;11:139-144.
7. Cheymol G, Poirier JM, Carrupt PA, Testa B, Weissenburger J, Levron JC, Snoeck E: Pharmacokinetics of beta-adrenoceptor blockers in obese and normal volunteers. Br J Clin Pharmacol 1997;43:563-570.
8. Cheymol G, Woestenborghs R, Snoeck E, Ianucci R, Le Moing JP, Naditch L, Levron JC, Poirier JM: Pharmacokinetic study and cardiovascular monitoring of nebivolol in normal and obese subjects. Eur J Clin Pharmacol 1997;51:493-498.
9. Galletti F, Fasano ML, Ferrara LA, Groppi A, Montagna M, Mancini M: Obesity and beta-blockers: influence of body fat on their kinetics and cardiovascular effects. J Clin Pharmacol 1989;29:212-216.